Coherus Confirms Filing Plans For Ranibizumab And Bevacizumab

Both Biosimilar Filings Have Experienced Delays

 
• By Dean Rudge

Coherus BioSciences aims to have four biosimilars on the market by 2023, including ranibizumab and bevacizumab for which it has provided updated timelines for planned US Food and Drug Administration filings.

FDAEntrance_1200x675
Coherus expects ranibizumab will be filed with the FDA midway through 2021 • Source: Shutterstock

More from Biosimilars

More from Products